Roles of PI3k pan-inhibitors and PI3k-d inhibitors in allergic lung inflammation: systematic review and a meta-analysis

Y. Lee (Jeonju, Republic of Korea), J. Kim (Jeonju, Republic of Korea), J. Jeong (Jeonju, Republic of Korea), S. Kwon (Jeonju, Republic of Korea), S. Kim (Jeonju, Republic of Korea)

Source: Virtual Congress 2020 – Management of allergy, asthma and COPD
Session: Management of allergy, asthma and COPD
Session type: E-poster session
Number: 231
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Y. Lee (Jeonju, Republic of Korea), J. Kim (Jeonju, Republic of Korea), J. Jeong (Jeonju, Republic of Korea), S. Kwon (Jeonju, Republic of Korea), S. Kim (Jeonju, Republic of Korea). Roles of PI3k pan-inhibitors and PI3k-d inhibitors in allergic lung inflammation: systematic review and a meta-analysis. 231

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Profiling the impact of two JAK inhibitors in a pre-clinical model of allergic asthma
Source: Virtual Congress 2020 – Scientific advances in airway pharmacology
Year: 2020


Inhibition of Pim1 kinase, new therapeutic approach in virus-induced asthma exacerbations
Source: Eur Respir J 2016; 47: 783-791
Year: 2016



A phosphatidylinositol 3-kinase Inhibitor strongly suppressed pulmonary vascular remodeling in a murine model of allergic vasculitis
Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions
Year: 2015

Leukotriene receptor antagonists for allergic rhino-sinusitis: a systematic review and meta-analysis
Source: Eur Respir J 2003; 22: Suppl. 45, 109s
Year: 2003

RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014

RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation
Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017
Year: 2017



Role of ras protoncogene in survival of patients with lung cancer: a systematic literature review and meta-analysis
Source: Eur Respir J 2004; 24: Suppl. 48, 478s
Year: 2004

AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015


Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients
Source: International Congress 2019 – Advances in COPD pharmacology
Year: 2019

ONX0912, a novel proteasome inhibitor for the treatment of lung fibrosis?
Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases
Year: 2012

Anti IL-17 with or without Rho kinase inhibitor in mice with chronic allergic pulmonary inflammation
Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology
Year: 2017

High-altitude alpine therapy and lung function in asthma: systematic review and meta-analysis
Source: ERJ Open Res 2016: 00097-2015
Year: 2016



Inhaled corticosteroids in asthma and longitudinal change in lung function: a systematic review and meta-analysis
Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies
Year: 2019


Association between cyclooxygenase inhibitor use and efficacy of immunotherapy: a retrospective study
Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer
Year: 2020


Inhibitors of PDE4 delay eosinophil apoptosis
Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population
Year: 2005


In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systems
Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases
Year: 2013

Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation
Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents
Year: 2017



The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice
Source: International Congress 2019 – Novel targets and mechanisms in asthma
Year: 2019




The role of EGFR expression in the survival of patients with lung cancer: a systematic review of the literature with meta-analysis
Source: Eur Respir J 2001; 18: Suppl. 33, 478s
Year: 2001

Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma
Source: Annual Congress 2009 - Preclinical models in drug development
Year: 2009